The Impact of Glucocorticoid Replacement Regimens on Metabolic Outcome and Comorbidity in Hypopituitary Patients
The DOI matches its Crossref record; 44 of the 48 references it cites were found in a registry or an index.
Abstract
Background: Hypopituitary patients with untreated GH deficiency and patients on inappropriately high doses of glucocorticoid (GC) share certain clinical features. Objective: The aim of the study was to examine the influence of GC substitution on clinical characteristics in hypopituitary patients before and after GH replacement therapy. Method: A total of 2424 hypopituitary patients within the KIMS (Pfizer International Metabolic Database) were grouped according to ACTH status. Comparisons were performed between subjects on hydrocortisone (HC) (n = 1186), cortisone acetate (CA) (n = 487), and prednisolone/dexamethasone (n = 52), and ACTH-sufficient patients (AS) (n = 717) before and after 1 yr of GH treatment in terms of body mass index, waist and hip circumference, blood pressure, glucose, glycosylated hemoglobin (HbA1c), serum lipids, IGF-I, and comorbidity. Hydrocortisone equivalent (HCeq) doses were calculated, and measurements were adjusted for sex and age. Results: At baseline, the HC group had increased total cholesterol, triglycerides, waist circumference, and HbA1c, and the prednisolone/dexamethasone group had increased waist/hip ratio as compared with AS. After HCeq dose adjustment, the HC group retained higher HbA1c than the CA group. GC-treated patients showed a dose-related increase in serum IGF-I, body mass index, triglycerides, low-density lipoprotein cholesterol and total cholesterol levels. Subjects with HCeq doses less than 20 mg/d (n = 328) at baseline did not differ from AS in metabolic endpoints. The 1-yr metabolic response to GH was similar in all GC groups and dose categories. All new cases of diabetes (n = 12), stroke (n = 8), and myocardial infarction (n = 3) during GH treatment occurred in GC-treated subjects. Conclusion: HCeq doses of at least 20 mg/d in adults with hypopituitarism are associated with an unfavorable metabolic profile. CA replacement may have metabolic advantages compared with other GCs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Retrospective studies of patients taking higher doses of glucocorticoids in some cases, including prednisolone or dexamethasone, appear to show a tendency to adverse metabolic consequences including weight gain, dyslipidemia, and diabetes mellitus (102).”
From Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [102]
In the citing paper
“When patients cut their GC dose in half (from 20-30 mg to 10-15 mg HC daily), mean body weight decreased by 7.1 kg after 6-12 months (209).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [209]
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423 · cited 1×
“Serum total cholesterol (TC) (15), triglycerides (16), and high-density lipoprotein cholesterol (HDL-C) (17) were measured as previously described, and low-density lipoprotein cholesterol (LDL-C) was calculated by the Friedewald formula (18).”
MethodSerum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide.
Fossati, P., & Prencipe, L. (1982) · Clinical Chemistry · doi:10.1093/clinchem/28.10.2077 · Cited by 2,905 · cited 1×
“Serum total cholesterol (TC) (15), triglycerides (16), and high-density lipoprotein cholesterol (HDL-C) (17) were measured as previously described, and low-density lipoprotein cholesterol (LDL-C) was calculated by the Friedewald formula (18).”
MethodCholesterol determination in high-density lipoproteins separated by three different methods.
Lopes-Virella, M. F., Stone, P., Ellis, S., & Colwell, J. A. (1977) · Clinical Chemistry · doi:10.1093/clinchem/23.5.882 · Cited by 1,841 · cited 5×
“This study was carried out in Eu- First Published Online August 8, 2006 Abbreviations: AE, Adverse event; AS, ACTH-sufficient (patients); BMI, body mass index; BP, blood pressure; CA, cortisone acetate; CI, confidence interval; DHEA, dehydroepiandrostenedione; DHEAS, DHEA sulfate; DM, diabetes mellitus; DX, dexamethas…”
MethodInfluentialGlucocorticoid-Induced Osteoporosis: Pathogenesis and Management
Lukert, B. P., & Raisz, L. G. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-5-352 · Cited by 1,066
Association between premature mortality and hypopituitarism
Tomlinson, J., Holden, N., Hills, R., Wheatley, K., Clayton, R., Bates, A., Sheppard, M., & Stewart, P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04006-x · Cited by 1,006 · cited 1×
“This could explain some of the metabolic features and increased cardiovascular mortality associated with severe GHD (9).”
BackgroundThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“ease, with no safe lower dose threshold (38, 39).”
BackgroundDaily cortisol production rate in man determined by stable isotope dilution/mass spectrometry
ESTEBAN, N. V., LOUGHLIN, T., YERGEY, A. L., ZAWADZKI, J. K., BOOTH, J. D., WINTERER, J. C., & LORIAUX, D. L. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-1-39 · Cited by 481 · cited 8×
“Recently, a reduction in GC dose has been advocated because physiological cortisol production has been shown to be lower than previously thought (10).”
BackgroundInfluentialCanalis, E. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.10.3441 · Cited by 463
Brabant, G., von zur Mühlen, A., Wüster, C., Ranke, M. B., Kratzsch, J., Kiess, W., Ketelslegers, J.-M., Wilhelmsen, L., Hulthén, L., Saller, B., et al. (2003) · Hormone Research in Paediatrics · doi:10.1159/000071871 · Cited by 360 · cited 1×
“In subsequent years, a chemiluminescence immunoassay was used (Nichols Advantages system) (20).”
MethodSelf-citationAbs, R., Bengtsson, B., Hernberg‐Ståhl, E., Monson, J. P., Tauber, J., Wilton, P., & Wüster, C. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00695.x · Cited by 267 · cited 2×
“The design of the KIMS survey is as previously described (12).”
BackgroundMethodSelf-citationOptimizing Growth Hormone Replacement Therapy by Dose Titration in Hypopituitary Adults
Drake, W. M., Coyte, D., Camacho‐Hübner, C., Jivanji, N. M., Kaltsas, G., Wood, D., Trainer, P. J., Grossman, A. B., Besser, G. M., & Monson, J. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.11.3913 · Cited by 236 · cited 1×
“At the inception of KIMS, GH was administered according to dose schedules based on body weight or body surface area, but subsequently, in the late 1990s, a more individualized schedule was instituted in most centers (13, 14) aiming to normalize IGF-I.”
MethodSelf-citationGlucocorticoid replacement therapy: are patients over treated and does it matter?
Peacey, S. R., Guo, C., Robinson, A. M., Price, A., Giles, M. A., Eastell, R., & Weetman, A. P. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.780907.x · Cited by 205 · cited 1×
“More recent studies have demonstrated a safe reduction toward a mean daily dose of 20 mg (26, 27) for most patients.”
BackgroundDehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies
Tchernof, A., & Labrie, F. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510001 · Cited by 187 · cited 1×
“High DHEAS concentrations have been suggested to be protective for cardiovascular disease (33) and exert a favorable influence on insulin sensitivity (34, 35), but data are conflicting (33, 36, 37).”
BackgroundMoore, J. S., Monson, J. P., Kaltsas, G., Putignano, P., Wood, P. J., Sheppard, M. C., BESSER, G. M., Taylor, N., & Stewart, P. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.11.6108 · Cited by 176 · cited 1×
“11 HSD1 activity is inhibited by GH and IGF-I in acromegaly (6) and is increased in GHD (7, 8), predicting augmented tissue exposure to GCs in GHD.”
BackgroundSelf-citationIndividualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults
Johannsson, G., Rosén, T., & Bengtsson, B. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.3271123.x · Cited by 172 · cited 1×
“At the inception of KIMS, GH was administered according to dose schedules based on body weight or body surface area, but subsequently, in the late 1990s, a more individualized schedule was instituted in most centers (13, 14) aiming to normalize IGF-I.”
MethodSelf-citationAn assessment of optimal hydrocortisone replacement therapy
Howlett, T. A. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.1340955.x · Cited by 169
Lie, R. F., Schmitz, J. M., Pierre, K. J., & Gochman, N. (1976) · Clinical Chemistry · doi:10.1093/clinchem/22.10.1627 · Cited by 161 · cited 1×
“Serum total cholesterol (TC) (15), triglycerides (16), and high-density lipoprotein cholesterol (HDL-C) (17) were measured as previously described, and low-density lipoprotein cholesterol (LDL-C) was calculated by the Friedewald formula (18).”
MethodAndrogen Deficiency in Women with Hypopituitarism
Miller, K. K., Sesmilo, G., Schiller, A., Schoenfeld, D., Burton, S., & Klibanski, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7246 · Cited by 131 · cited 1×
“have lower serum androgen levels, including DHEA sulfate (DHEAS), than AS (31, 32).”
BackgroundGelding, S. V., Taylor, N. F., Wood, P. J., Noonan, K., Weaver, J. U., Wood, D. F., & Monson, J. P. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.3641180.x · Cited by 124 · cited 1×
“11 HSD1 activity is inhibited by GH and IGF-I in acromegaly (6) and is increased in GHD (7, 8), predicting augmented tissue exposure to GCs in GHD.”
BackgroundSelf-citationWeaver, J. U., Theventhiran, L., Noonan, K., Burrin, J. M., Taylor, N. F., Norman, M. R., & Monson, J. P. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb01830.x · Cited by 120 · cited 1×
“11 HSD1 activity is inhibited by GH and IGF-I in acromegaly (6) and is increased in GHD (7, 8), predicting augmented tissue exposure to GCs in GHD.”
BackgroundSelf-citationEffect of Dehydroepiandrosterone Replacement on Insulin Sensitivity and Lipids in Hypoadrenal Women
Dhatariya, K., Bigelow, M. L., & Nair, K. S. (2005) · Diabetes · doi:10.2337/diabetes.54.3.765 · Cited by 114 · cited 1×
“High DHEAS concentrations have been suggested to be protective for cardiovascular disease (33) and exert a favorable influence on insulin sensitivity (34, 35), but data are conflicting (33, 36, 37).”
BackgroundAndrogen Deficiency in Women with Hypopituitarism
Miller, K. K. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.2.561 · Cited by 83
Clinical pharmacology of the anti‐inflammatory steroids
Liddie, G. W. (1961) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196125615 · Cited by 82
Cardiovascular function and glucocorticoid replacement in patients with hypopituitarism
Dunne, F. P., Elliot, P., Gammage, M. D., Stallard, T., Ryan, T., Sheppard, M. C., & Stewart, P. M. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb02928.x · Cited by 70 · cited 1×
“Another study found no difference in fasting glucose or HbA1c after a reduction of HC from 30 to 15 mg over a 3-month period (30).”
BackgroundRosén, T., Johannsson, G., Johansson, J.-O., & Bengtsson, B.-Å. (2008) · Hormone Research · doi:10.1159/000184245 · Cited by 67
Self-citationAl‐Shoumer, K. A. S., Beshyah, S. A., Niththyananthan, R., & Johnston, D. G. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb02602.x · Cited by 62 · cited 1×
“Hypopituitary patients on GC replacement showed reduced insulin sensitivity on the mornings HC was given compared with mornings without HC in one study (28), but this was not confirmed in a further study (29).”
Dehydroepiandrosterone, dehydroepiandrosterone sulphate and cardiovascular disease
Khaw, K. (1996) · Journal of Endocrinology · doi:10.1677/joe.0.150s149 · Cited by 57 · cited 1×
“High DHEAS concentrations have been suggested to be protective for cardiovascular disease (33) and exert a favorable influence on insulin sensitivity (34, 35), but data are conflicting (33, 36, 37).”
BackgroundAmelioration of Insulin Resistance in Diabetes With Dehydroepiandrosterone
Buffington, C. K., Pourmotabbed, G., & Kitabchi, A. E. (1993) · The American Journal of the Medical Sciences · doi:10.1097/00000441-199311000-00010 · Cited by 52 · cited 1×
“High DHEAS concentrations have been suggested to be protective for cardiovascular disease (33) and exert a favorable influence on insulin sensitivity (34, 35), but data are conflicting (33, 36, 37).”
BackgroundSwords, F. M., Carroll, P. V., Kisalu, J., Wood, P. J., Taylor, N. F., & Monson, J. P. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01894.x · Cited by 52 · cited 3×
“HSD1 with a reduction of serum cortisol levels (11).”
BackgroundInfluentialSelf-citationEndocrine and metabolic diseases. Adrenal diseases.
BESSER, G. M., & Jeffcoate, W. J. (1976) · BMJ · doi:10.1136/bmj.1.6007.448 · Cited by 43 · cited 1×
“Historically, 30 mg of oral HC daily was the dose of choice for patients with adrenal insufficiency (25).”
BackgroundMaccario, M., Tassone, F., Gauna, C., Oleandri, S. E., Aimaretti, G., Massimo, P., Grottoli, S., Pflaum, C. D., Strasburger, C., & Ghigo, E. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1440251 · Cited by 41 · cited 1×
“A direct hepatic effect of GC on IGF-I secretion after GH administration has been suggested (42), and it is also possible that higher serum insulin concentrations in GC-treated patients may augment the serum IGF-I response during GH replacement.”
BackgroundBoland, E. W. (1952) · BMJ · doi:10.1136/bmj.1.4758.559 · Cited by 38
Isidori, A. M., Kaltsas, G., Perry, L., Burrin, J. M., BESSER, G. M., & Monson, J. P. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01759.x · Cited by 35
Self-citationMETABOLIC EFFECTS OF METACORTANDRALONE AND METACORTANDRACIN
Bunim, J. J., Black, R. L., Bollet, A. J., & Pechet, M. M. (1955) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1955.tb42485.x · Cited by 33
Radioimmunoassay of the Somatomedins/Insulin-like Growth Factors
Underwood, L. E., & Murphy, M. G. (1987) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-71809-0_23 · Cited by 32 · cited 5×
“Serum IGF-I measurements were performed between 1994 and October 1997 by Kabi Pharmacia (Stockholm, Sweden) (19) and thereafter until November 2002 by Sahlgrenska University Hospital (Gothenburg, Sweden), using a RIA (Nichols Institute Diagnostic, San Juan Capistrano, CA).”
MethodInfluentialChristiansen, J. J., Gravholt, C. H., Fisker, S., Møller, N., Andersen, M., Svenstrup, B., Bennett, P., Ivarsen, P., Christiansen, J. S., & Jørgensen, J. O. L. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01810 · Cited by 29 · cited 1×
“High DHEAS concentrations have been suggested to be protective for cardiovascular disease (33) and exert a favorable influence on insulin sensitivity (34, 35), but data are conflicting (33, 36, 37).”
BackgroundClinical investigation of 11β-hydroxysteroid dehydrogenase
Walker, B. R., & Best, R. (1995) · Endocrine Research · doi:10.3109/07435809509030454 · Cited by 26
[Thyrotropin releasing hormone and serum levels of catecholamines as well as 11-hydroxycorticoids].
Brisse, B., Wagner, H., Vosberg, H., Hurbesch, M., Böckel, K., & Hauss, W. H. (1971) · PubMed · Cited by 24
Boland, E. W. (1958) · PubMed · Cited by 23
IGF-I levels rise and GH responses to GHRH decrease during long-term prednisone treatment in man
Borges, M.-H. S., Pinto, A. C. A., Ninno, F. B. D., Camacho‐Hübner, C., Grossman, A. B., Kater, C. E., & Lengyel, A. M. J. (1999) · Journal of Endocrinological Investigation · doi:10.1007/bf03345472 · Cited by 21 · cited 1×
“There are some previous data suggesting that GC augments serum IGF-I generation (40) only in the presence of GH (41).”
BackgroundDexamethasone does not increase IGF-I and IGFBP-3 levels in man in the absence of endogenous GH
Finamor, F. E., & Lengyel, A. M. J. (2001) · Journal of Endocrinological Investigation · doi:10.1007/bf03343944 · Cited by 4 · cited 1×
“There are some previous data suggesting that GC augments serum IGF-I generation (40) only in the presence of GH (41).”
BackgroundEffects of morning cortisol replacement on glucose and lipid metabolism in GH-treated subjects
Segerlantz, M., Bramnert, M., Thomasson, R., Manhem, P., Laurila, E., & Groop, L. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510701 · Cited by 4 · cited 1×
“Hypopituitary patients on GC replacement showed reduced insulin sensitivity on the mornings HC was given compared with mornings without HC in one study (28), but this was not confirmed in a further study (29).”
Wei, L. H. C., MacDonald, T. M., & Walker, B. (2003) · Endocrine Abstracts · Cited by 1
Cited by
Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1710 · Cited by 1,769
“Retrospective studies of patients taking higher doses of glucocorticoids in some cases, including prednisolone or dexamethasone, appear to show a tendency to adverse metabolic consequences including weight gain, dyslipidemia, and diabetes mellitus (102).”
BackgroundHormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Complications of Cushing's syndrome: state of the art
Pivonello, R., Isidori, A. M., De Martino, M. C., Newell-Price, J., Biller, B. M. K., & Colao, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00086-3 · Cited by 641
Glucocorticoids and cardiovascular disease
Walker, B. R. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0455 · Cited by 529
Diagnosis and management of adrenal insufficiency
Bancos, I., Hahner, S., Tomlinson, J., & Arlt, W. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70142-1 · Cited by 467
Metadata
- Authors
- Filipsson, H., Monson, J. P., Koltowska-Häggström, M., Mattsson, A., & Johannsson, G.
- Affiliations
- Department of Endocrinology (H.F., G.J.), Sahlgrenska Academy at Gothenburg’s University, SE-413 45 Gothenburg, Sweden
- St Bartholomew's Hospital (GB)
- KIGS/KIMS/ACROSTUDY Medical Outcomes (M.K.-H., A.M.), Endocrine Care, Pfizer, SE-191 90 Sollentuna, Sweden
- Pfizer (Sweden) (SE)
- University of Gothenburg (SE)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-10-01
- Volume
- 91
- Issue
- 10
- Pages
- 3954-3961
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2137769079
- Cited by
- 321
- References
- 48
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 25 · 2023: 12 · 2022: 13 · 2021: 17 · 2020: 24 · 2019: 18 · 2018: 16 · 2017: 16 · 2016: 25 · 2015: 20 · 2014: 23 · 2013: 12 · 2012: 19
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Chalmers Research (Chalmers University of Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- hypopituitarism, glucocorticoid replacement therapy, cortisol, cortisone acetate, prednisolone, dexamethasone, growth hormone replacement therapy, metabolic profile, body mass index, waist circumference, serum lipids, HbA1c, insulin-like growth factor I, diabetes mellitus, stroke, myocardial infarction, comorbidities, glucocorticoid dose
- MeSH terms
- Adrenocorticotropic Hormone, Adult, Aged, Female, Glucocorticoids, Humans, Hypopituitarism, Insulin-Like Growth Factor I, Lipids, Male, Middle Aged, Risk Factors, Growth Hormone, Comorbidity, Body Mass Index, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.